Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
about
Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaCutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyThe class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanismsThe clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesHistone deacetylase inhibitors in Hodgkin lymphoma.Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.Potential non-oncological applications of histone deacetylase inhibitors.Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor responseEndogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas.Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma.Histone deacetylase inhibition and dietary short-chain Fatty acids.The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.Caenorhabditis elegans histone deacetylase hda-1 is required for morphogenesis of the vulva and LIN-12/Notch-mediated specification of uterine cell fatesThe epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells.A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.New developments in the pathology of malignant lymphoma: a review of the literature published from August to November 2009.Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells.Clinical development of panobinostat in classical Hodgkin's lymphoma.Targeted molecular therapy in peripheral T-cell lymphomas.Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013).The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.Recent advances in understanding and managing T-cell lymphoma.Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines.Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma.The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
P2860
Q26851166-042F682B-F1ED-4C40-B277-AA037815271FQ27024076-66DF2862-007A-4031-BEFE-010C558D555EQ28082536-A272B7FF-7692-4456-8C5F-8E0C8E98E4D0Q33392081-BDF485A2-16EF-4CBE-B1A6-491B2D016156Q33705588-6C0F3C62-B264-453A-847C-3F7877DE3B20Q33761796-71498B82-900E-41AF-BF72-9ACA28B37ADEQ33829390-EB4073A9-66D4-4F36-B4E7-B9A90665813CQ33886267-42B11AC9-C50F-4EA7-8B8D-0EABD57998B4Q34414440-7C33529B-0B2D-4083-80B6-043D5A9C0BAEQ34414452-D5BE1439-FA88-4B56-A4A0-AA2A643F82E1Q34557179-226B888C-773C-46BB-8D0C-E5BA95F6E18AQ34707183-3907135F-9C46-4537-A277-358C2B9C5FF0Q35485587-AABF980B-97EA-4CB4-88C7-4CEA467F9502Q35741605-39DA53A2-BA14-4C5F-972A-AEF77CD6B9D5Q35975127-2886A3B6-E1EE-4A52-9D85-4FF2E04093ECQ36343613-A330F9D1-7339-4720-A41F-BD12C3863699Q36470196-81FE1EE1-258F-44E1-B687-2FFAF385B502Q36814349-8B6D4A23-969A-4FCD-8ED8-095DF596D831Q36858061-1FB66746-60D4-4667-8178-4BF9FD009237Q36926692-F788B039-3040-42A9-B7FE-F67DF74C1FB3Q37079542-DDFB3ACF-8143-4C45-A476-AE5684400CB4Q37577442-2F5AFA62-7D3D-4172-A9B1-55B4874E81EBQ37589239-6E2690F0-3CCB-48C2-A785-8E872692C234Q37716646-546DE922-B894-45E3-B9C5-62DE4EC6F335Q37724028-C2B3CA30-786F-4D48-B469-848D6B71E7E8Q37888710-FCF18D29-1955-42FE-9354-EA0D5F164BE6Q37937044-F2CD420E-DEB9-4C63-AE24-CDB6F9256A60Q37944565-4F3F961E-17D2-498A-B15A-5A390F17E001Q38176396-A4CE3B3B-E07B-4937-B6D0-BA67851FF95BQ38260795-FB39893C-2F17-497C-89EE-C1DA3AB156C8Q38466376-E00DC904-E7ED-4B6B-91DD-790C840B6151Q38765451-E6408494-734C-4C59-ABB8-498052577363Q38833038-BD8A5E85-C93E-4859-9606-EB590D470403Q43269281-E08A430C-B944-4338-9DE2-995D65700C70Q47131247-9985F19B-678D-4EF8-ADA7-42507D8096EAQ48034709-01AA490E-D763-4397-9D4C-5FFDFE7FD0CDQ48601823-BFF96E0D-9D05-491B-BE70-1AB414A24D4EQ54641838-6D633991-9209-4BDD-8865-ED09A4F4A5E5Q54967313-9E85F97C-20A8-4BF1-9D02-DB2D3EE9EC84Q58792448-9D586117-C93F-4AFC-A7F5-5731822C5298
P2860
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Expression of histone deacetyl ...... pment of selective inhibitors.
@ast
Expression of histone deacetyl ...... pment of selective inhibitors.
@en
type
label
Expression of histone deacetyl ...... pment of selective inhibitors.
@ast
Expression of histone deacetyl ...... pment of selective inhibitors.
@en
prefLabel
Expression of histone deacetyl ...... pment of selective inhibitors.
@ast
Expression of histone deacetyl ...... pment of selective inhibitors.
@en
P2093
P2860
P50
P1476
Expression of histone deacetyl ...... opment of selective inhibitors
@en
P2093
Anas Younes
Daniela Buglio
Georgios Georgakis
Noor M Khaskhely
Sattva S Neelapu
P2860
P304
P356
10.1111/J.1365-2141.2009.07887.X
P407
P577
2009-09-22T00:00:00Z